NCCN Oncology Research Program (ORP)
NCCN ORP Mission Statement
The NCCN ORP fosters innovation and knowledge discovery that improve the lives of patients with cancer.
Guiding Principles:
- Study both FDA-approved and investigational agents/devices, to seek novel enhanced, effective, and efficient cancer therapy.
- Develop new insights into cancer care delivery outcomes and quality, as well as identify solutions to barriers affecting optimal cancer management.
- Increase opportunities for NCCN Member Institution faculty to participate in oncologic investigation and support those who are, or will become, leaders in cancer research.
- Demonstrate that constructive, appropriate, and transparent collaboration between academia and industry results in valuable knowledge and improved cancer management.
- Ensure the dissemination of knowledge gained through the program to the medical community at large through presentations at meetings and/or publication in peer-reviewed journals.
Current Opportunities
NCCN and Pfizer Investigator Sponsored Research for Understanding the Mechanisms and Formulating the Optimal Management of Hematological Toxicity of PARPi in the Treatment of Prostate Cancer – Proposal Submission Deadline Extended until Wednesday, September 18, 2024. Now open to all investigators in the United States.
Now Accepting Abstracts for the 2025 NCCN Annual Conference General Poster Session - Submit an abstract by Wednesday, October 30, 2024.
NCCN and Taiho Request for Proposals (RFP) Opportunity: Phase I/II Clinical Trials of Tipiracil/Trifluridine (TAS-102) and/or Futibatinib (TAS-120) for Gastrointestinal Cancers – Submit proposals by Tuesday, November 12, 2024. Open to NCCN Member Institutions only.
View the NCCN ORP Press Releases
View the NCCN ORP Scientific Publications
View the NCCN ORP Disclosure Policy